Page 20 - Read Online
P. 20
Page 340 Seno et al. Cancer Drug Resist 2019;2:335-50 I http://dx.doi.org/10.20517/cdr.2019.01
A
B
C
Figure 1. Design of a drug screening system against miPSCs-derived CSCs (miPS-CSCs). A: Schematic representation of drug screening
against miPS-CSCs. Stem cell populations of miPS-CSCs were concentrated in the presence of puromycin and CM of bulk culture. Drug
screening was performed under treatment with CMs. Each test compound was added at a concentration of 1 μmol/L. Cell viability was
determined by MTT assay after 48 h of treatment; B: representative results of screening with compounds categorized as anticancer drugs
(n = 2). The miPS-LLCcm, miPS-LLCcm primary, miPS-LLCcm LMT, and miPS-B16cm cell lines were used for the screening. Relative cell
viabilities were presented as normalized values against DMSO control; C: IC50 values of daunorubicin against various miPS-LLCcm were
determined. BALB/c 3T3 cells, L1210s cells, Hela cells, and miPSCs were additionally tested for comparison
[20]
dependent mitochondrial apoptosis pathway . In addition to the upregulated expression of certain target
genes, p53 represses the expression of various genes. For instance, p53 has been demonstrated to repress
